Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2.

Abstract

Aging and pre-existing conditions in older patients increase severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severity and its complications, although the causes remain unclear. Apart from acute pulmonary syndrome, Coronavirus 2019 (COVID-19) can increasingly induce chronic conditions. Importantly, SARS-CoV-2 triggers de novo type 2 diabetes mellitus (T2DM) linked to age-associated cardiovascular disease (CVD), cancers, and neurodegeneration. Mechanistically, SARS-CoV-2 induces inflammation, possibly through damage-associated molecular pattern (DAMP) signaling and 'cytokine storm,' causing insulin resistance and the adiponectin (APN) paradox, a phenomenon linking metabolic dysfunction to chronic disease. Accordingly, preventing the APN paradox by suppressing APN-related inflammatory signaling might prove beneficial. A better understanding could uncover novel therapies for SARS-CoV-2 and its chronic disorders.

• Authors: Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, Ryoko Wada, Eliezer Masliah, Makoto Hashimoto
• Journal: Drug discovery today (Drug Discov Today) Vol. 26 Issue 8 Pg. 2036-2044 (08 2021) ISSN: 1878-5832 [Electronic] England
• PMID: 33775925 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Chemical References

• Adiponectin

Topics

• Adiponectin (metabolism)
• Aging (physiology)
• COVID-19 (immunology, metabolism)
• Chronic Disease
• Diabetes Mellitus, Type 2 (immunology)
• Humans
• Inflammation (metabolism)
• Paracrine Communication (physiology)
• SARS-CoV-2 (pathogenicity, physiology)